Zastosowanie preparatu ranibizumab u pacjentów z odwarstwieniem nabłonka barwnikowego w przebiegu wysiękowej postaci AMD
Administration of Ranibizumab in Patients with Pigment Epithelium Detachment due to Wet Form of AMD
Małgorzata Wojnar, Agnieszka Bartczak, Zofia Mariak
Klinika Okulistyki Uniwersytetu Medycznego w Białymstoku
Kierownik: prof. dr hab. n. med. Zofia Mariak
Summary: Aim of the study: To evaluate the efficacy of anti-VEGF treatment in patients with pigment epithelium detachment (PED) due to wet form of AMD.
Material and Methods: 13 eyes in 11 patients were observed with PED and choroidal neovascularization (CNV) due to wet form of AMD. Ranibizumab was administered in monthly cycles for following 3 months.
Results: Visual acuity was improved in 8 patients, stayed the same in 4 cases and was reduced in 1 patient after the administered therapy. The mean visual acuity was improved from 20/83 to 20/58 (p = 0.046). The central retinal thickness was reduced to 254 µm – mean 83 µm (p =0.04).
Conclusions: The administration of ranibizumab in difficult cases of wet AMD with PED seems to be reasonable, though the potential risk of pigment epithelium rupture. This therapy increases the chance for the AMD patients with PED for saving their vision.
Słowa kluczowe: zwyrodnienie plamki związane z wiekiem (AMD), PED, CNV.
Keywords: age-related macular degeneration (AMD), PED, CNV.